Baker Bros. Advisors’s Tenax Therapeutics TENX Stock Holding History

Baker Bros. Advisors’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11	Closed	-$171K	–	118
2017 Q4	$171K	Hold	11	–	–	﹤0.01%	121
2017 Q3	$126K	Buy	11 +7	+175%	+$104K	﹤0.01%	119
2017 Q2	$98K	Buy	+4	New	+$66.6K	﹤0.01%	118
2017 Q1	–	Sell	-13	Closed	-$819K	–	130
2016 Q4	$819K	Hold	13	–	–	0.01%	112
2016 Q3	$972K	Hold	13	–	–	0.01%	113
2016 Q2	$1.07M	Hold	13	–	–	0.01%	114
2016 Q1	$861K	Hold	13	–	–	0.01%	117
2015 Q4	$1.38M	Hold	13	–	–	0.01%	115
2015 Q3	$1.26M	Buy	13 +2	+18%	+$229K	0.01%	114
2015 Q2	$1.31M	Buy	+11	New	+$1.25M	0.01%	115

Other funds holding TENX

FWP

FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baker Bros. Advisors's TENX Position: Q1 2018 in Review

Baker Bros. Advisors sold out of Tenax Therapeutics (TENX) in Q1 2018, closing a stake of 11 shares — an estimated $171K sold.

Baker Bros. Advisors first reported a position in TENX in Q2 2015 and held it in 10 quarters. The position peaked at $1.38M in Q4 2015. 6 funds tracked by Wall St. Rank hold TENX as of Q1 2018.

Baker Bros. Advisors reported no remaining Tenax Therapeutics position as of Q1 2018 after selling out during the quarter.
Baker Bros. Advisors sold 11 Tenax Therapeutics shares in Q1 2018, an estimated $171K.
Baker Bros. Advisors first reported a position in Tenax Therapeutics in Q2 2015 and held it in 10 quarters.
Baker Bros. Advisors's Tenax Therapeutics position peaked at $1.38M in Q4 2015.
6 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2018.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.